Pharmaceutical Treatments of Osteoporosis

Bruce H. Mitlak, David Burr, Matthew Allen

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Osteoporosis is a common disease and the societal burden of osteoporosis-related fractures is substantial. Progress in the development of new therapies has occurred rapidly over the beginning of the 2000s to include nutritional and pharmacological (both anticatabolic and anabolic). These US Food and Drug Administration-approved agents all significantly reduce fracture risk, albeit through slightly different mechanisms. Anticatabolic agents, bisphosphonates, estrogen, selective estrogen receptor modulators, calcitonin, and anti-RANKL antibody (denosumab) target osteoclast development or activity to reduce remodeling. The only approved anabolic agent, teriparatide, targets osteoblast activity to enhance bone formation. The efficacy of these agents individually has let to interest in assessing various combination treatments in an attempt to maximize fracture risk reduction. Emerging therapies to reduce fracture include both anticatabolic (cathepsin K inhibitors) and anabolic (anti-sclerostin antibody) agents.

Original languageEnglish
Title of host publicationBasic and Applied Bone Biology
PublisherElsevier Inc.
Pages345-363
Number of pages19
ISBN (Print)9780124160156
DOIs
StatePublished - Aug 12 2013

Fingerprint

Osteoporosis
Anti-Idiotypic Antibodies
Cathepsin K
Pharmaceutical Preparations
Teriparatide
Selective Estrogen Receptor Modulators
Anabolic Agents
Fracture Fixation
Diphosphonates
Calcitonin
Osteoclasts
United States Food and Drug Administration
Risk Reduction Behavior
Osteoblasts
Osteogenesis
Estrogens
Therapeutics
Pharmacology
Denosumab

Keywords

  • Anabolic
  • Anti-sclerostin antibody
  • Anticatabolic
  • Antiremodeling
  • Bisphosphonate
  • Calcium
  • Cathepsin K inhibitor
  • Combination treatment
  • Denosumab
  • Estrogen
  • Selective estrogen receptor modulators
  • Teriparatide
  • Vitamin D

ASJC Scopus subject areas

  • Medicine(all)
  • Dentistry(all)

Cite this

Mitlak, B. H., Burr, D., & Allen, M. (2013). Pharmaceutical Treatments of Osteoporosis. In Basic and Applied Bone Biology (pp. 345-363). Elsevier Inc.. https://doi.org/10.1016/B978-0-12-416015-6.00017-4

Pharmaceutical Treatments of Osteoporosis. / Mitlak, Bruce H.; Burr, David; Allen, Matthew.

Basic and Applied Bone Biology. Elsevier Inc., 2013. p. 345-363.

Research output: Chapter in Book/Report/Conference proceedingChapter

Mitlak, BH, Burr, D & Allen, M 2013, Pharmaceutical Treatments of Osteoporosis. in Basic and Applied Bone Biology. Elsevier Inc., pp. 345-363. https://doi.org/10.1016/B978-0-12-416015-6.00017-4
Mitlak BH, Burr D, Allen M. Pharmaceutical Treatments of Osteoporosis. In Basic and Applied Bone Biology. Elsevier Inc. 2013. p. 345-363 https://doi.org/10.1016/B978-0-12-416015-6.00017-4
Mitlak, Bruce H. ; Burr, David ; Allen, Matthew. / Pharmaceutical Treatments of Osteoporosis. Basic and Applied Bone Biology. Elsevier Inc., 2013. pp. 345-363
@inbook{3957019ce0b6481f82cf456ddcf59c38,
title = "Pharmaceutical Treatments of Osteoporosis",
abstract = "Osteoporosis is a common disease and the societal burden of osteoporosis-related fractures is substantial. Progress in the development of new therapies has occurred rapidly over the beginning of the 2000s to include nutritional and pharmacological (both anticatabolic and anabolic). These US Food and Drug Administration-approved agents all significantly reduce fracture risk, albeit through slightly different mechanisms. Anticatabolic agents, bisphosphonates, estrogen, selective estrogen receptor modulators, calcitonin, and anti-RANKL antibody (denosumab) target osteoclast development or activity to reduce remodeling. The only approved anabolic agent, teriparatide, targets osteoblast activity to enhance bone formation. The efficacy of these agents individually has let to interest in assessing various combination treatments in an attempt to maximize fracture risk reduction. Emerging therapies to reduce fracture include both anticatabolic (cathepsin K inhibitors) and anabolic (anti-sclerostin antibody) agents.",
keywords = "Anabolic, Anti-sclerostin antibody, Anticatabolic, Antiremodeling, Bisphosphonate, Calcium, Cathepsin K inhibitor, Combination treatment, Denosumab, Estrogen, Selective estrogen receptor modulators, Teriparatide, Vitamin D",
author = "Mitlak, {Bruce H.} and David Burr and Matthew Allen",
year = "2013",
month = "8",
day = "12",
doi = "10.1016/B978-0-12-416015-6.00017-4",
language = "English",
isbn = "9780124160156",
pages = "345--363",
booktitle = "Basic and Applied Bone Biology",
publisher = "Elsevier Inc.",

}

TY - CHAP

T1 - Pharmaceutical Treatments of Osteoporosis

AU - Mitlak, Bruce H.

AU - Burr, David

AU - Allen, Matthew

PY - 2013/8/12

Y1 - 2013/8/12

N2 - Osteoporosis is a common disease and the societal burden of osteoporosis-related fractures is substantial. Progress in the development of new therapies has occurred rapidly over the beginning of the 2000s to include nutritional and pharmacological (both anticatabolic and anabolic). These US Food and Drug Administration-approved agents all significantly reduce fracture risk, albeit through slightly different mechanisms. Anticatabolic agents, bisphosphonates, estrogen, selective estrogen receptor modulators, calcitonin, and anti-RANKL antibody (denosumab) target osteoclast development or activity to reduce remodeling. The only approved anabolic agent, teriparatide, targets osteoblast activity to enhance bone formation. The efficacy of these agents individually has let to interest in assessing various combination treatments in an attempt to maximize fracture risk reduction. Emerging therapies to reduce fracture include both anticatabolic (cathepsin K inhibitors) and anabolic (anti-sclerostin antibody) agents.

AB - Osteoporosis is a common disease and the societal burden of osteoporosis-related fractures is substantial. Progress in the development of new therapies has occurred rapidly over the beginning of the 2000s to include nutritional and pharmacological (both anticatabolic and anabolic). These US Food and Drug Administration-approved agents all significantly reduce fracture risk, albeit through slightly different mechanisms. Anticatabolic agents, bisphosphonates, estrogen, selective estrogen receptor modulators, calcitonin, and anti-RANKL antibody (denosumab) target osteoclast development or activity to reduce remodeling. The only approved anabolic agent, teriparatide, targets osteoblast activity to enhance bone formation. The efficacy of these agents individually has let to interest in assessing various combination treatments in an attempt to maximize fracture risk reduction. Emerging therapies to reduce fracture include both anticatabolic (cathepsin K inhibitors) and anabolic (anti-sclerostin antibody) agents.

KW - Anabolic

KW - Anti-sclerostin antibody

KW - Anticatabolic

KW - Antiremodeling

KW - Bisphosphonate

KW - Calcium

KW - Cathepsin K inhibitor

KW - Combination treatment

KW - Denosumab

KW - Estrogen

KW - Selective estrogen receptor modulators

KW - Teriparatide

KW - Vitamin D

UR - http://www.scopus.com/inward/record.url?scp=84902051621&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84902051621&partnerID=8YFLogxK

U2 - 10.1016/B978-0-12-416015-6.00017-4

DO - 10.1016/B978-0-12-416015-6.00017-4

M3 - Chapter

SN - 9780124160156

SP - 345

EP - 363

BT - Basic and Applied Bone Biology

PB - Elsevier Inc.

ER -